ArticleScandinavian journal of immunology2015
Epitope-based peptide vaccine design and target site depiction against Ebola viruses: an immunoinformatics study.
Article in Scandinavian journal of immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Immunoinformatics prediction of potential B-cell and T-cell epitopes as effective vaccine candidates for eliciting immunogenic responses against Epstein-Barr virus.Biomedical journal · 2021Pooled it
- Molecular Epidemiology of Peste des Petits Ruminants Virus Circulating in Fat-Tailed Sheep in Bangladesh.Veterinary medicine and science · 2026Article
- Computational design of an mRNA vaccine targeting antifungal-resistant Lomentospora prolificans.Scientific reports · 2025Article
- Deep learning in next-generation vaccine development for infectious diseases.Molecular therapy. Nucleic acids · 2025Review
- Immunoreactivity Analysis of MHC-I Epitopes Derived from the Nucleocapsid Protein of SARS-CoV-2 via Computation and Vaccination.Vaccines · 2024Article
- In Silico Analysis of a Candidate Multi-epitope Peptide Vaccine Against Human Brucellosis.Molecular biotechnology · 2024Article
- Designing of a new multi-epitope vaccine against Leishmania major using Leish-F1 epitopes: An In-silico study.PloS one · 2024Article
- Designing a multi-epitope vaccine candidate against human rhinovirus C utilizing immunoinformatics approach.Frontiers in immunology · 2024Article
- Antimicrobial peptides and their potential application in antiviral coating agents.Colloids and surfaces. B, Biointerfaces · 2022Review
- Article
- Designing AbhiSCoVac - A single potential vaccine for all 'corona culprits': Immunoinformatics and immune simulation approaches.Journal of molecular liquids · 2022Article
- Novel In Silico mRNA vaccine design exploiting proteins of M. tuberculosis that modulates host immune responses by inducing epigenetic modifications.Scientific reports · 2022Article
- Epitope-based Multi-variant SARS-Cov-2 Vaccine Design: Shared Epitopes Among the Natural SARS-Cov-2 Spike Glycoprotein and 5 of its Variants (D614G, α, β, γ, δ) with HighJournal of immunological sciences · 2021Article
- Implementation ofHeliyon · 2021Article
- Genome based evolutionary lineage of SARS-CoV-2 towards the development of novel chimeric vaccine.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2020Article
- Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics approach.International journal of biological macromolecules · 2020Article
- Immunological Perspective for Ebola Virus Infection and Various Treatment Measures Taken to Fight the Disease.Pathogens (Basel, Switzerland) · 2020Review
- An immunoinformatics study on the spike protein of SARS-CoV-2 revealing potential epitopes as vaccine candidates.Heliyon · 2020Article
- Immunoinformatics approach for predicting epitopes in HN and F proteins of Porcine rubulavirus.PloS one · 2020Article
- Epitope Prediction by Novel Immunoinformatics Approach: A State-of-the-art Review.International journal of peptide research and therapeutics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ebola viruses (EBOVs) have been identified as an emerging threat in recent year as it causes severe haemorrhagic fever in human. Epitope-based vaccine design for EBOVs remains a top priority because a mere progress has been made in this regard. Another reason is the lack of antiviral drug and licensed vaccine although there is a severe outbreak in Central Africa. In this study, we aimed to design an epitope-based vaccine that can trigger a significant immune response as well as to prognosticate inhibitor that can bind with potential drug target sites using various immunoinformatics and docking simulation tools. The capacity to induce both humoral and cell-mediated immunity by T cell and B cell was checked for the selected protein. The peptide region spanning 9 amino acids from 42 to 50 and the sequence TLASIGTAF were found as the most potential B and T cell epitopes, respectively. This peptide could interact with 12 HLAs and showed high population coverage up to 80.99%. Using molecular docking, the epitope was further appraised for binding against HLA molecules to verify the binding cleft interaction. In addition with this, the allergenicity of the epitopes was also evaluated. In the post-therapeutic strategy, docking study of predicted 3D structure identified suitable therapeutic inhibitor against targeted protein. However, this computational epitope-based peptide vaccine designing and target site prediction against EBOVs open up a new horizon which may be the prospective way in Ebola viruses research; the results require validation by in vitro and in vivo experiments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.